-
Split-Ticket Voters Buoy Democrats in Key Senate Races
In the battleground state of Arizona and other important pockets of the country, polling suggests that voters backing the former president are eschewing Republican Senate candidates.
-
Harris and Liz Cheney Will Team Up for a Pitch to Blue-Wall Suburbs
The vice president and her top Republican surrogate will appear together for “moderated conversations” in the suburbs of Philadelphia, Detroit and Milwaukee.
-
The Enigmatic Universe Exploring the Mysteries of the Cosmos
The Enigmatic Universe: Exploring the Mysteries of the Cosmos The universe, with its vast expanse of stars, galaxies, and unknown phenomena, has captivated humanity for centuries. From the ancient civilizations who gazed up at the night sky in wonder to the modern-day astronomers peering through powerful telescopes, the mysteries of the cosmos have inspired countless…
-
NYDFS Issues Industry Letter on Risks Arising from Artificial Intelligence
On October 16, 2024, the New York Department of Financial Services (DFS) issued an Industry Letter to regulated entities entitled “Cybersecurity Risks Arising from Artificial Intelligence and Strategies to Combat Related Risks.”…By: Robinson+Cole Data Privacy + Security Insider
-
Key Takeaways from Claim Examples in the 2024 AI Patent Eligibility Guidance: A 3-Part Series
Part 1 – On July 17, 2024, the U.S. Patent and Trademark Office (the Office) released new guidance on subject matter eligibility, entitled “The 2024 Patent Subject Matter Eligibility Guidance Update Including on Artificial Intelligence” (2024 AI SME Update). The 2024 AI SME Update is a lifeline for patent prosecutors prosecuting AI patent applications because…
-
NYDFS Issues Guidance on Artificial Intelligence-related Cybersecurity Risks
On October 16, 2024, the New York Department of Financial Services (“NYDFS”) issued an industry letter covering Cybersecurity Risks Arising from Artificial Intelligence and Strategies to Combat Related Risks (the “Industry Letter”). The Industry Letter contains guidance for entities regulated by NYDFS (“Covered Entities”) in assessing and responding to cybersecurity risks related to the use…
-
Teva’s Denosumab Biosimilar Candidate is Accepted for Review by FDA and EMA
On October 8, 2024, Teva Pharmaceutical Industries Ltd. announced that the United States Food and Drug Administration (FDA) has accepted, and the European Medicines Agency (EMA) has validated, applications for TVB-009P, a biosimilar candidate to Amgen’s PROLIA® (denosumab) that treats osteoporosis……By: Goodwin
-
Accord BioPharma’s Stelara® Biosimilar Imuldosa™ Approved by FDA
On October 10, 2024, the FDA approved Accord BioPharma’s Imuldosa™ (ustekinumab-srlf), the fifth biosimilar of Janssen / Johnson & Johnson’s Stelara® (ustekinumab). Imuldosa™ was developed by Dong-A ST in collaboration with Meij Seika Pharma, and Accord is responsible for commercialization in the U.S….By: Venable LLP
-
Worker’s Comp Versus Personal Injury in California
According to the United States Bureau of Labor Statistics, a reported 419,000 private-sector employees in California sustained workplace injuries and illnesses in 2022. Workplace incidents in the state claimed 508 employees’ lives in 2022 in the state….By: Maison Law
-
Novacure’s Wearable Lung Cancer Treatment Device, Optune Lua, Receives FDA Approval
The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell lung cancer (NSCLC). The device utilizes portable transducer arrays placed on the skin to deliver alternating electrical fields, termed Tumor Treating Fields (TTFs), thereby disrupting malignant cell division while leaving healthy cells largely unaffected….By: Knobbe Martens
